Motti Sapir has upgraded Clover Health (CLOV) to a Buy, citing improving fundamentals and an underappreciated path to profitability. Meanwhile, Daniel Jones upgraded Kimberly-Clark (KMB) to a soft Buy as strategic transformation initiatives and the pending Kenvue acquisition strengthen its outlook.
On the downgrade side, Dhierin Bechai has moved Tesla (TSLA) from Hold to Sell, pointing to persistent overvaluation and slow progress on autonomy targets. The Techie has also downgraded UnitedHealth Group (UNH) to Hold amid regulatory headwinds and margin compression concerns following a surprise Medicare Advantage rate proposal.
Upgrades
-
Clover Health Investments (CLOV): Upgrade Hold to Buy by Motti Sapir. The analyst believes the market has swung too negative on the stock, missing the clear turnaround coming in 2026 as older member cohorts become profitable.
“I think CLOV finally looks like a real contrarian buy. Most investors are stuck on the recent losses and aren’t giving enough credit to the huge turnaround coming in 2026, or how steady the profits from older members will be. … I think the risk-reward now leans toward long-term buyers, as long as Clover delivers in the next year.”
-
Kimberly-Clark (KMB): Upgrade Hold to soft Buy by Daniel Jones. The analyst highlights improving profitability metrics and attractive relative valuation, especially with potential synergies from the Kenvue acquisition.
“From what I can see, the overall picture for shareholders of Kimberly-Clark is positive. Yes, revenue dropped recently. But organic revenue is up. Profits and cash flows are improving thanks to the initiatives that management has embarked on. … And while there is some risk associated with its purchase of Kenvue, even if synergies aren’t realized, the company is still relatively appealing.”
Downgrades
-
Tesla (TSLA): Downgrade Hold to Sell by Dhierin Bechai. The analyst argues that Tesla’s valuation remains inflated while execution on autonomy and robotics continues to lag, with no near-term support for the stock price.
“I am downgrading the stock to sell as the EV/EBITDA multiple remains high, and we are not seeing realistic targets for FSD Level 5 and a humanoid robot. The capitalization on the autonomy stack is simply too far away. … Tesla should not be valued according to car manufacturer valuation standards, but, as I discuss in this report, it is for autonomy, which has not materialized for years.”
-
UnitedHealth Group (UNH): Downgrade Buy to Hold by The Techie. The analyst cites a combination of regulatory uncertainty from the proposed flat Medicare Advantage rate increase and rising medical care ratios that threaten near-term profitability.
“I’m downgrading the stock to a hold and see more downside ahead in the near term as the market prices in a tougher reimbursement environment and structurally higher medical cost trends. … UNH’s rising medical care ratio is a real fundamental concern. While Optum remains a bright spot and continues to be the strategic asset that differentiates UNH from peers, its strength is no longer enough to fully offset pressure in the insurance business.”